SCHEMBL6414387

SCHEMBL6414387

Cc1cc2cc(C(=O)N[C@@H]3C[C@@H]4CCN(C4)C3)ncn2c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 7/20 0.70
SMYD3 Q9H7B4 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAB9A P51151 1/20 0.34
KDM5A P29375 1/20 0.33
USP30 Q70CQ3 2/20 0.33
CNR2 P34972 1/20 0.33
MLLT3 P42568 1/20 0.33
MLLT1 Q03111 1/20 0.33
KDM4E B2RXH2 2/20 0.32
HSD17B10 Q99714 2/20 0.32
ACKR3 P25106 1/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414385 1.00 CHRNA7 (0.70) CHRNA7SMYD3SMN1; SMN2NPC1ALDH1A1
SCHEMBL6413691 1.00 CHRNA7 (0.70) CHRNA7SMYD3SMN1; SMN2NPC1ALDH1A1
SCHEMBL6410907 0.87 CHRNA7 (0.70) CHRNA7SMYD3USP30MLLT3MLLT1
SCHEMBL6410342 0.87 CHRNA7 (0.70) CHRNA7SMYD3USP30MLLT3MLLT1
SCHEMBL6417861 0.87 CHRNA7 (0.70) CHRNA7SMYD3USP30MLLT3MLLT1
SCHEMBL6417865 0.87 CHRNA7 (0.70) CHRNA7SMYD3USP30MLLT3MLLT1
SCHEMBL6413684 0.87 CHRNA7 (0.70) CHRNA7SMYD3USP30MLLT3MLLT1
SCHEMBL6410348 0.87 CHRNA7 (0.70) CHRNA7SMYD3USP30MLLT3MLLT1
SCHEMBL6413393 0.85 CHRNA7 (0.56) CHRNA7SMN1; SMN2USP30KDM4EHSD17B10
SCHEMBL6411870 0.85 CHRNA7 (0.56) CHRNA7SMN1; SMN2USP30KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC 2005-09-29 US claimed
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC 2005-09-29 US disclosed
US-6858613-B2 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC. (US) 2005-02-22 US disclosed
EP-1476449-A1 FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-11-17 EP disclosed
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed
WO-2003070732-A1 FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease NAT1, CYP11B1, COASY CHRNA7 1475/4885SMYD3 4056/4885SMN1; SMN2 881/4885
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease CHRNA7, UGT2B7, CHRNA5 CHRNA7 1/4885SMYD3 3711/4885SMN1; SMN2 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.